AAV‐mediated Gene Therapy for Hereditary Deafness: Progress and Perspectives
2024

Gene Therapy for Hereditary Deafness

Sample size: 11 publication 10 minutes Evidence: high

Author Information

Author(s): Liyan Zhang, Fangzhi Tan, Jieyu Qi, Yicheng Lu, Xiaohan Wang, Xuehan Yang, Xiangyan Chen, Xinru Zhang, Jinyi Fan, Yinyi Zhou, Li Peng, Nianci Li, Lei Xu, Shiming Yang, Renjie Chai

Primary Institution: Southeast University

Hypothesis

Can gene therapy effectively treat hereditary deafness caused by genetic mutations?

Conclusion

Gene therapy has shown promising results in restoring hearing function in patients with hereditary deafness caused by specific genetic mutations.

Supporting Evidence

  • Gene therapy has restored hearing in over 20 types of genetic deafness model mice.
  • Clinical trials have shown significant improvements in auditory function in patients with OTOF mutations.
  • AAV vectors are the most commonly used for gene therapy in hereditary deafness.
  • Gene therapy has been effective in treating hereditary autosomal recessive deafness 9 (DFNB9).
  • Challenges remain due to the complexity of the inner ear and variations in gene mutations.

Takeaway

Scientists are using special medicine to help kids who can't hear because of their genes, and it's working really well!

Methodology

The review summarizes preclinical and clinical research on AAV-mediated gene therapy for hereditary deafness, focusing on advancements and challenges.

Limitations

The complexity of the inner ear structure and variations in gene mutations complicate the effectiveness of gene therapy.

Participant Demographics

The study involved children aged 5 to 8 years with hereditary deafness due to OTOF mutations.

Digital Object Identifier (DOI)

10.1002/advs.202402166

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication